In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Hemostasis tests help screen and identify patients with hemostatic defects. GlobalData uses proprietary data and analytics to provide a comprehensive report on the hemostasis tests devices market, including market shares of different players within New Zealand. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the hemostasis tests market in New Zealand was Siemens followed by Werfen Life, Diagnostica Stago, F. Hoffmann-La Roche, Abbott Laboratories, bioMerieux, Quidelortho, Bio-Rad Laboratories and Danaher.
Hemostasis tests includes the sub-segments Prothrombin time tests, Prothrombin time (PT) POC test, Prothrombin time laboratory tests, activated partial thromboplastin time (aPTT or PTT) tests, Activated partial thromboplastin time (aPTT) POC tests, Activated partial thromboplastin time (aPTT or PTT) laboratory tests, D-dimer tests, D-dimer POC test, and D-dimer laboratory tests. Laboratory tests: Any tests that require transporting of patient samples to a laboratory, including those with rapid turnaround times, are defined as laboratory or lab-based tests. Point Of Care Tests (POC): Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often ‘handheld’ or may be small portable analyzers. In the Hemostasis tests market, POC tests often include devices used in physician’s offices and for at-home monitoring.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the hemostasis tests devices market within New Zealand was expected to be over $1m in 2022.
For the latest complete market share analysis of hemostasis tests device market in New Zealand, buy the report here.